[{"address1": "7707 Gateway Boulevard", "address2": "Suite 140", "city": "Newark", "state": "CA", "zip": "94560", "country": "United States", "phone": "510 474 0170", "website": "https://www.protagonist-inc.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.", "fullTimeEmployees": 126, "companyOfficers": [{"maxAge": 1, "name": "Dr. Dinesh V. Patel Ph.D.", "age": 67, "title": "CEO, President, Secretary & Director", "yearBorn": 1957, "fiscalYear": 2024, "totalPay": 1366917, "exercisedValue": 41362, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Asif  Ali", "age": 50, "title": "Executive VP & CFO", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 805042, "exercisedValue": 586039, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Suneel K. Gupta Ph.D.", "age": 66, "title": "Executive Vice President of Clinical Development", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 896847, "exercisedValue": 7759965, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Arturo M. Molina FACP, M.D., M.S.", "age": 65, "title": "Chief Medical Officer", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 956912, "exercisedValue": 1160875, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mohammad  Masjedizadeh Ph.D.", "title": "Executive VP & CTO", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Newman  Yeilding", "title": "Executive VP, Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew M. Gosling J.D.", "age": 53, "title": "Executive VP and Chief Legal & Business Officer", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Carena  Spivey", "title": "Senior VP & Chief Human Resources Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ashok  Bhandari Ph.D.", "age": 60, "title": "EVP & Chief Discovery Officer", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Carter J. King", "age": 53, "title": "Executive Vice President of Business Development", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 7, "overallRisk": 8, "governanceEpochDate": 1761955200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 79.78, "open": 80.12, "dayLow": 76.7, "dayHigh": 80.64, "regularMarketPreviousClose": 79.78, "regularMarketOpen": 80.12, "regularMarketDayLow": 76.7, "regularMarketDayHigh": 80.64, "payoutRatio": 0.0, "beta": 2.202, "trailingPE": 120.515144, "forwardPE": -55.62238, "volume": 874394, "regularMarketVolume": 874394, "averageVolume": 1147375, "averageVolume10days": 938590, "averageDailyVolume10Day": 938590, "bid": 78.99, "ask": 79.66, "bidSize": 9, "askSize": 9, "marketCap": 4972495872, "fiftyTwoWeekLow": 33.31, "fiftyTwoWeekHigh": 93.25, "allTimeHigh": 93.25, "allTimeLow": 4.47, "priceToSalesTrailing12Months": 23.76717, "fiftyDayAverage": 68.5425, "twoHundredDayAverage": 53.40335, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 4407128064, "profitMargins": 0.21943001, "floatShares": 43369618, "sharesOutstanding": 62515666, "sharesShort": 6312028, "sharesShortPriorMonth": 6659476, "sharesShortPreviousMonthDate": 1757894400, "dateShortInterest": 1760486400, "sharesPercentSharesOut": 0.1015, "heldPercentInsiders": 0.01013, "heldPercentInstitutions": 1.15063, "shortRatio": 4.06, "shortPercentOfFloat": 0.1216, "impliedSharesOutstanding": 62211318, "bookValue": 10.336, "priceToBook": 7.695433, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": 45909000, "trailingEps": 0.66, "forwardEps": -1.43, "enterpriseToRevenue": 21.065, "enterpriseToEbitda": 220.026, "52WeekChange": 0.7105377, "SandP52WeekChange": 0.12121439, "quoteType": "EQUITY", "currentPrice": 79.54, "targetHighPrice": 112.0, "targetLowPrice": 65.0, "targetMeanPrice": 88.92308, "targetMedianPrice": 88.0, "recommendationMean": 1.41667, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 13, "totalCash": 576116992, "totalCashPerShare": 9.216, "ebitda": 20030000, "totalDebt": 10749000, "quickRatio": 12.938, "currentRatio": 13.048, "totalRevenue": 209216992, "debtToEquity": 1.665, "revenuePerShare": 3.313, "returnOnAssets": 0.0182, "returnOnEquity": 0.077989995, "grossProfits": 209216992, "freeCashflow": 53095000, "operatingCashflow": 65468000, "revenueGrowth": 0.008, "grossMargins": 1.0, "ebitdaMargins": 0.095740005, "operatingMargins": -9.85166, "financialCurrency": "USD", "symbol": "PTGX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "longName": "Protagonist Therapeutics, Inc.", "priceEpsCurrentYear": -42.233704, "fiftyDayAverageChange": 10.997498, "fiftyDayAverageChangePercent": 0.16044785, "twoHundredDayAverageChange": 26.13665, "twoHundredDayAverageChangePercent": 0.48941967, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.4 - Strong Buy", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1762554296, "regularMarketTime": 1762549201, "exchange": "NGM", "messageBoardId": "finmb_129263324", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1470922200000, "postMarketChangePercent": 0.0, "postMarketPrice": 79.54, "postMarketChange": 0.0, "regularMarketChange": -0.239998, "regularMarketDayRange": "76.7 - 80.64", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 1147375, "fiftyTwoWeekLowChange": 46.23, "fiftyTwoWeekLowChangePercent": 1.3878714, "fiftyTwoWeekRange": "33.31 - 93.25", "fiftyTwoWeekHighChange": -13.709999, "fiftyTwoWeekHighChangePercent": -0.14702412, "fiftyTwoWeekChangePercent": 71.053764, "earningsTimestampStart": 1762462800, "earningsTimestampEnd": 1762462800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": 0.66, "epsForward": -1.43, "epsCurrentYear": -1.88333, "regularMarketChangePercent": -0.300825, "regularMarketPrice": 79.54, "shortName": "Protagonist Therapeutics, Inc.", "displayName": "Protagonist Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-11-08"}]